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Abstract
Introduction In a study conducted by Annane, patients with
septic shock and unresponsive to adrenocorticotropic hormone
stimulation receiving low-dose steroid therapy had prolonged
survival but not significantly improved 28-day mortality. The
present study examines intravenous steroid use in PROWESS
(Recombinant Human Activated Protein C Worldwide
Evaluation in Severe Sepsis) patients meeting the Annane
enrollment criteria (AEC).
Methods Adrenocorticotropic hormone stimulation tests were
not done in PROWESS. Steroids were allowed but their use
was not directed. Patients were identified using AEC (all of:
randomization to study drug treatment within 8 hours of shock
onset; infection, fever, or hypothermia; tachycardia; systolic
blood pressure <90 mmHg on vasopressors; mechanical
ventilation; and one of urine <0.5 ml/kg per hour, lactic acidosis,
or arterial oxygen tension/inspired fractional oxygen <280). We
examined steroid use and mortality data; additional analyses
were done outside the 8-hour window.
Results Steroid-treated patients were older, had higher Acute
Physiology and Chronic Health Evaluation scores and more
organ dysfunctions, and were more commonly receiving
mechanical ventilation. Among patients meeting AEC,
regardless of steroid treatment (n = 97), mortality in the placebo
and drotrecogin alfa (activated) groups was 38% (19/50) and
28% (13/47), respectively (relative risk [RR] = 0.73, 95%
confidence interval [CI] 0.41–1.30). When using AEC but
excluding the requirement for randomization within 8 hours of
shock onset (n = 612), placebo mortality was 38% (118/313)
and drotrecogin alfa (activated) mortality was 29% (88/299; RR
= 0.78, 95% CI 0.62–0.98). Using AEC but excluding the 8-
hour window and with steroids initiated at baseline and/or
infusion (n  = 228) resulted in mortality for placebo and
drotrecogin alfa (activated) groups of 43% (51/118) and 33%
(36/110), respectively (RR = 0.76, 95% CI 0.54–1.06).
Conclusion Patients with severe sepsis from the PROWESS
trial who were likely to respond to low-dose steroids according
to the AEC were those patients at a high risk for death.
However, when using the AEC, regardless of steroid use,
patients exhibited a survival benefit from treatment with
drotrecogin alfa (activated).
Introduction
Corticosteroid therapy in sepsis and septic shock has been
investigated for more than 50 years [1]. Over this period there
have been dozens of trials examining various patient popula-
tions, assessing different corticosteroids in a wide range of
dosing regimens, and employing methodologies that are
diverse in form and quality [1-15]. Results have varied widely,
with some studies favoring the control group and some favor-
ing the treatment group (low-dose use); others have shown vir-
tually no difference in outcome, and still other studies
(particularly those examining high-dose steroids) have indi-
cated that steroid therapy is harmful [3,4,9,16]. Recently, a
small study of patients with community-acquired pneumonia
[17] showed a positive effect of steroid treatment. However,
findings from several investigators suggest that steroid
AEC = Annane enrollment criteria.Critical Care    Vol 9 No 5    Levy et al.
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treatment should be limited to patients who have adrenal insuf-
ficiency [18-21].
The hypothalamic–pituitary–adrenal axis plays an important
role in the body's ability to respond to stress. Patients who
develop septic shock and who are consequently maximally
stressed, in response to an infection, may exhibit adrenal insuf-
ficiency. Insufficiency of the adrenal system correlates with
increased risk for mortality associated with severe sepsis and/
or septic shock [22]. Adrenal replacement therapy in patients
with adrenal failure may be a logical addition to standard care
in patients with severe sepsis and vasopressor dependent
shock. Annane and colleagues [22] demonstrated that the
response to a short corticotropin test could potentially be
used to identify patients with relative adrenal insufficiency who
are at high risk for death related to septic shock. In another
recent, randomized trial of 300 patients with septic shock,
Annane and coworkers [15] found that 229 patients (about
two-thirds) had adrenal insufficiency, as determined using the
250 µg corticotropin stimulation test. In this subgroup mortal-
ity at 28 days was not significantly less among those who
received corticosteroids (53%) than in the placebo group
(63%;  P  = 0.10). Patients who had adrenal insufficiency
appeared to have prolonged median survival (16.5 days for
corticosteroid treatment versus 14 days for placebo), but
these values and the difference in 28-day mortality between
treatment group and placebo were not significant.
A recent review and meta-analysis [18] assessing the effects
of corticosteroids on mortality in patients with severe sepsis
and septic shock found that, for all published trials, use of cor-
ticosteroids did not significantly affect mortality overall. The
studies by Annane and coworkers did show that corticosteroid
treatment might reduce mortality in a subgroup of septic shock
patients with well defined adrenal insufficiency. However, even
with corticosteroid plus fludrocortisone treatment, more than
half of that subgroup of patients died, clearly indicating the
importance of additional therapies to reduce mortality not only
in this subgroup but also in the overall population of septic
shock patients, with or without adrenal insufficiency.
There are currently no published data on the use of drotrec-
ogin alfa (activated) with corticosteroids in the treatment of
severe sepsis. The Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis (PROWESS) trial
[23] was a phase III study designed to evaluate drotrecogin
alfa (activated) for the treatment of patients with severe sepsis
at high risk for death (e.g. as determined by an Acute Physiol-
ogy and Chronic Health Evaluation II score ≥ 25 and/or two or
more organ dysfunctions). The present study examines steroid
use in PROWESS patients with severe sepsis and septic
shock.
Materials and methods
In the PROWESS trial, severe sepsis patients were randomly
assigned to receive either drotrecogin alfa (activated) at a
dose of 24 µg/kg per hour, or placebo, administered intrave-
nously for 96 hours. Concomitant use of steroids was allowed
but was not required or specified by the protocol in PROW-
ESS. The duration and route but not dose of steroids was
recorded. For the present analysis, patients were identified
using all of the Annane enrollment criteria (AEC): randomiza-
tion of treatment with drotrecogin alfa (activated) or placebo
within 8 hours of onset of shock; infection, fever, or hypother-
mia; tachycardia; systolic blood pressure <90 mmHg on vaso-
pressors; mechanical ventilation; and one of urine output <0.5
ml/kg per hour, lactic acidosis, or arterial oxygen tension/frac-
tional inspired oxygen <280. In the PROWESS trial patients
were classified as being in septic shock at baseline if they met
any of the following criteria for at least 1 hour despite ade-
quate fluid resuscitation or having documented adequate
intravascular volume status, at any time within the 6 hours
before the start of infusion of drotrecogin alfa (activated) or
placebo: arterial systolic blood pressure ≤ 90 mmHg; mean
arterial pressure ≤ 70 mmHg; or need for vasopressors
(defined as dopamine ≥ 5  µg/kg per min or noradrenaline
[norepinephrine], adrenaline [epinephrine], or phenylephrine
at any dose) to maintain systolic blood pressure ≥ 90 mmHg or
mean arterial pressure ≥ 70 mmHg.
We also analyzed data from PROWESS patients selected
using the AEC but without the criterion of drotrecogin alfa
(activated) or placebo treatment initiation within 8 hours of the
onset of septic shock. The adrenocorticotropic hormone stim-
ulation test was not done in PROWESS, and so subgroups
related to adrenal insufficiency could not be evaluated.
The characteristics of patients receiving steroids at baseline or
during infusion were compared with those of patients who did
not receive steroids at baseline or during infusion. Continuous
baseline characteristics (e.g. age) were analyzed using one-
way analysis of variance. Categorical baseline characteristics
were analyzed using Pearson's χ 2 test.
Figure 1
Patient population Patient population. AEC = Annane enrollment criteria.
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Pearson's χ 2 tests were used for all 28-day mortality subgroup
analyses, which compared drotrecogin alfa (activated) treated
patients with placebo patients. The logit methodology was
used to calculate relative risks and associated 95% confi-
dence intervals.
Results
Baseline characteristics (e.g. age, disease severity, etc.) were
not different between placebo and drotrecogin alfa (activated)
treated patients in the PROWESS trial [23]. The distribution
of patients from PROWESS according to AEC is shown in
Fig. 1. Of the 1690 PROWESS patients, 36.2% met the AEC
without the 8-hour time restriction (i.e. randomization to study
drug treatment within 8 hours of shock onset) and 5.7% met
the AEC with the 8-hour time restriction. These two groups
were then further subdivided into patients receiving steroids
and those not receiving steroids. Patients receiving steroid
treatment at either severe sepsis onset or during drotrecogin
alfa (activated) infusion were classified as treated with
steroids.
Table 1 lists the baseline disease severity measures for
PROWESS patients treated or not treated with steroids
(PROWESS overall; AEC not considered). Patients treated
with steroids were older, and had higher mean Acute Physiol-
ogy and Chronic Health Evaluation II scores and more organ
dysfunctions than did patients not receiving steroids. Patients
were also more likely to receive ventilator support in the steroid
treatment group at baseline. PROWESS 28-day all-cause
Table 1
Baseline disease severity measures for patients treated versus not treated with steroids
Characteristic/parameter Steroidsa No steroids P value
Age (years; mean ± SD [n])
Overall 62 ± 15.9 (586) 60 ± 17.3 (1104) 0.024b
Drotrecogin alfa (activated) 62 ± 16.1 (291) 60 ± 17.7 (559) 0.126b
Placebo 62 ± 15.7 (295) 60 ± 16.8 (545) 0.098b
APACHE II (mean ± SD [n])
Overall 26.4 ± 7.6 (586) 23.9 ± 7.6 (1104) <0.001b
Drotrecogin alfa (activated) 26.6 ± 7.7 (291) 23.5 ± 7.4 (559) <0.001b
Placebo 26.2 ± 7.5 (295) 24.3 ± 7.9 (545) <0.001b
Number of organ dysfunctions (mean ± SD [n])
Overall 2.5 ± 1.1 (586) 2.3 ± 1.1 (1104) 0.018b
Drotrecogin alfa (activated) 2.5 ± 1.1 (291) 2.3 ± 1.1 (559) 0.020b
Placebo 2.5 ± 1.1 (295) 2.4 ± 1.1 (545) 0.301b
Baseline shockd (% [n])
Overall 74% (432) 70% (768) 0.073c
Drotrecogin alfa (activated) 75% (217) 68% (381) 0.521c
Placebo 73% (215) 71% (387) 0.565c
Baseline vasopressor (% [n])
Overall 64% (374) 62% (683) 0.429c
Drotrecogin alfa (activated) 62% (179) 60% (337) 0.728c
Placebo 66% (195) 63% (346) 0.450c
Baseline ventilator (% [n])
Overall 80% (471) 73% (804) <0.001c
Drotrecogin alfa (activated) 79% (230) 70% (393) 0.006c
Placebo 82% (241) 75% (411) 0.037c
aPatients receiving steroids at baseline or infusion were classified as receiving steroids. bBy analysis of variance. cBy Pearson's χ 2 test. dBaseline 
shock was shock at any time within 6 hours prior to drotrecogin alfa (activated) or placebo infusion. APACHE, Acute Physiology and Chronic 
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mortality by steroid exposure either at severe sepsis onset or
drotrecogin alfa (activated) infusion is shown in Fig. 2.
Figure 3 illustrates the 28-day all-cause mortality for PROW-
ESS patients meeting the AEC, either including or excluding
the 8-hour time window (study treatment within 8 hours of
onset of shock). A survival benefit was observed for drotrec-
ogin alfa (activated)-treated patients regardless of whether
they were treated with steroids at baseline or during infusion,
or whether they met the AEC with or without the 8-hour time
criteria.
Discussion
The use of steroid therapy in the treatment of sepsis and sep-
tic shock has been a controversial issue for many decades.
Recent data [15] indicate that physiologic doses of hydrocor-
tisone and fludrocortisone used in combination can reduce the
risk for death in patients with relative adrenal insufficiency and
Figure 2
28-Day all-cause mortality for PROWESS patients 28-Day all-cause mortality for PROWESS patients. Infusion refers to infusion period plus 1 calendar day after termination of infusion. DrotAA, drot-
recogin alfa (activated); PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.
Figure 3
28-Day all-cause mortality for PROWESS Patients meeting the Annane enrollment criteria 28-Day all-cause mortality for PROWESS Patients meeting the Annane enrollment criteria. Steroids received at baseline and/or during the infusion 
period. AEC = Annane enrollment criteria; DrotAA, drotrecogin alfa (activated); PROWESS, Recombinant Human Activated Protein C Worldwide 
Evaluation in Severe Sepsis.
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septic shock. However, the patient population in that study
remained at a high risk for death, as indicated by a 28-day mor-
tality rate of 53% in the treatment group in which steroids were
most effective. Guidelines from the Surviving Sepsis Cam-
paign [24] suggested that stress dose steroid therapy should
be used for septic shock; however, they further stated that
there are no documented studies showing that stress doses of
steroids improve the outcome of sepsis without shock unless
a patient's history indicates steroid use or adrenal dysfunction.
In the recent meta-analysis conducted by Annane and cowork-
ers [18] it was concluded that steroids should be given to
patients only when absolute or relative adrenal insufficiency is
present. However, the definition for adrenal insufficiency has
varied in the few trials in which it was used to evaluate patients
for steroid treatment [12,15]. A further area of controversy is
whether serum cortisol levels should be measured as total or
free cortisol. It was recently reported that severe hypopro-
teinemia frequently results in concentrations of serum total
cortisol in critically ill patients that are lower than expected,
whereas free cortisol levels give a more accurate indication of
response to corticotropin stimulation [25] and thus provide
better identification of patients with adrenal insufficiency.
The PROWESS trial was a phase III placebo-controlled study
that evaluated drotrecogin alfa (activated) for the treatment of
patients with severe sepsis [23]. In that study drotrecogin alfa
(activated) treatment was associated with a significant abso-
lute reduction in mortality rate of 6.1% (relative risk reduction
19.4%;  P  = 0.005), and of 12.8% (relative risk reduction
29.2%; P = 0.0002) in the subpopulation of patients who
were at high risk for death, which led to its approval by the US
Food and Drug Administration.
This is the first report on the use of drotrecogin alfa (activated)
with corticosteroids in the treatment of severe sepsis. An anal-
ysis of the PROWESS data indicates that 36.2% of the 1690
PROWESS patients met the AEC without the 8-hour time
restriction and 5.7% met the criteria with the 8-hour time
restriction for enrollment in the study by Annane and cowork-
ers [15]. Limitations of our study include the fact that we did
not know the dose or particular type of corticosteroid drug
administered and that we did not know the responsiveness of
patients to the adrenocorticotropic hormone test.
When examining data from PROWESS, mortality among pla-
cebo patients does not differ regardless of whether steroid
was given at baseline or during infusion, or whether one
applies the 8-hour time restriction or not. Where no steroid
was given, the mortality in the two groups still does not differ,
suggesting that the timing of steroid treatment alone does not
affect mortality. These data further demonstrate an absence of
effect of steroid treatment on the potential benefit from drot-
recogin alfa (activated) treatment.
The mortality rate from severe sepsis in the PROWESS trial
was substantially lower than that previously reported by
Annane and coworkers [15,18]. However, the PROWESS
trial employed different exclusion criteria than did Annane and
coworkers; in particular, the PROWESS trial excluded mori-
bund patients and patients not expected to survive 28 days
because of an underlying medical disease.
Drotrecogin alfa (activated) reduced mortality in PROWESS
patients with severe sepsis at high risk for death [23]. Patients
at high risk for death were more likely to be treated with ster-
oids. In the PROWESS trial the use of steroids did not signif-
icantly affect the treatment benefit from drotrecogin alfa
(activated).
Conclusion
Drotrecogin alfa (activated) reduces mortality in patients with
severe sepsis at high risk for death, as indicated by meeting
the AEC for steroid use. Therefore, we conclude that severe
sepsis patients with vasopressor dependent shock should be
evaluated for drotrecogin alfa (activated) therapy, particularly if
steroids are considered. This is because, regardless of steroid
use, these patients have demonstrated survival benefit from
treatment with drotrecogin alfa (activated).
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Key messages
•  Meeting criteria for steroid use by Annane study entry 
criteria identifies a patient at high risk of death.
•  Patients receiving steroids in PROWESS were older, 
had higher APACHE II scores, more organ dysfunc-
tions, and were more commonly receiving mechanical 
ventilation than those who did not receive steroids.
•  Drotrecogin alfa (activated) provides a survival benefit 
to these high-risk patients regardless of steroid use.Critical Care    Vol 9 No 5    Levy et al.
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